NICEVIVA
MONOGRAPH SPEC LATEST 2024

Glutathione (Reduced)

ANTIOXIDANTS · Evidence Monograph

Glutathione (Reduced) is an evidence-graded antioxidants monograph evaluated across 11 peer-reviewed PubMed studies (0 meta-analyses, 0 systematic reviews, and 0 randomized controlled trials). Current clinical evidence is rated GRADE Low (2.0 / 4.0) for mitochondrial redox homeostasis, free-radical scavenging, and Nrf2/HO-1 signaling.

Evidence Grade (GRADE) Low (2.0 / 4.0)
Indexed PubMed Studies 11 Studies
Meta-Analyses · Reviews 0 Meta · 0 Systematic Reviews
Randomized Trials (RCT) 0 RCTs (0 Double-Blind)
Cumulative Participants 0 Quantitative Studies
Trial Duration Range 4 weeks · 3 weeks · 21 days
Reading Time ~6 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for mitochondrial redox homeostasis, free-radical scavenging, and Nrf2/HO-1 signaling (supported by 11 indexed PubMed studies, GRADE Low).
  2. 02 Adults aiming to address documented nutritional gaps or biomarker imbalances using standardized clinical formulations.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Stabilized Bioavailable Redox Formulation (e.g., Ubiquinol / R-ALA / Liposomal)
Acidic antioxidants (such as alpha-lipoic acid) irritate the esophagus when taken fasting; pair fat-soluble antioxidants with meals.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Sustained recovery and absence of post-dose heartburn.
Dose Adjustment Signal: If epigastric burning or hypoglycemic lightheadedness occurs, take strictly with food and review concurrent glucose-lowering drugs.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Immediately After a Meal
Post-prandial dosing prevents esophageal reflux and enhances lymphatic uptake of lipophilic redox cofactors.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary antioxidants clinical efficacy (11 PubMed studies)
Quantitative biomarker & outcome analysis (0 studies with effect-size/sample data)
Randomized controlled trial verification (0 RCTs · 0 double-blind)
Systematic review & meta-analysis synthesis (0 meta-analyses · 0 reviews)
01

What Is Glutathione (Reduced) & Why Does Form Matter?

Glutathione (Reduced) is classified under ANTIOXIDANTS and has been investigated across 11 peer-reviewed PubMed publications for its role in mitochondrial redox homeostasis, free-radical scavenging, and Nrf2/HO-1 signaling.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (see individual study protocols).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Glutathione (Reduced) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (0 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Glutathione (Reduced) acts on pathways governing mitochondrial redox homeostasis, free-radical scavenging, and Nrf2/HO-1 signaling. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Acidic antioxidants (such as alpha-lipoic acid) irritate the esophagus when taken fasting; pair fat-soluble antioxidants with meals.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Glutathione (Reduced) an overall evidence rating of GRADE Low (2.0 / 4.0) based on 11 PubMed studies: 0 meta-analyses, 0 systematic reviews, and 0 randomized controlled trials (0 double-blind).

Representative peer-reviewed findings include: • PMID:32131656 (2021) — "Comparative Evaluation of Clinical Efficacy and Safety of Collagen Laminin-Based Dermal Matrix Combined With Resveratrol Microparticles (Dermalix) and Standard Wound Care for Diabetic Foot Ulcers." (Dx provided 2 times faster wound healing and decreased oxidative stress.) • PMID:38877681 (2024) — "Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF₂ /HO-1 signaling." (Conclusion: The present study introduces clear evidence that the administration of LIX and TIC can improve meta) • PMID:31482490 (2019) — "Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells." (Furthermore, the addition of glutathione reduced ethyl ester (GSH-OEt), recovered intracellular GSH level, and cell viability with reduced the intracellular ROS level.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Stabilized Bioavailable Redox Formulation (e.g., Ubiquinol / R-ALA / Liposomal). Acidic antioxidants (such as alpha-lipoic acid) irritate the esophagus when taken fasting; pair fat-soluble antioxidants with meals.

Clinical Trial Dosing & Timing: Optimal timing window: PM 12:30 · Immediately After a Meal (Post-prandial dosing prevents esophageal reflux and enhances lymphatic uptake of lipophilic redox cofactors.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Sustained recovery and absence of post-dose heartburn.

Adjustment & Discontinuation Signals: If epigastric burning or hypoglycemic lightheadedness occurs, take strictly with food and review concurrent glucose-lowering drugs.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Glutathione (Reduced), but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · Immediately After a Meal) with a full glass of water.
  • Start at a conservative single-serving dose for the first 5–7 days to verify gastrointestinal tolerance.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (11 Studies)

01
CLINICAL STUDY The international journal of lower extremity wounds (2021) PMID: 32131656 ↗
Comparative Evaluation of Clinical Efficacy and Safety of Collagen Laminin-Based Dermal Matrix Combined With Resveratrol Microparticles (Dermalix) and Standard Wound Care for Diabetic Foot Ulcers.
Clinical Trial Synthesis 2021 Randomized Controlled Trial (RCT) published in The international journal of lower extremity wounds. Key conclusion: Dx provided 2 times faster wound healing and decreased oxidative stress.
View Original PubMed Abstract ↓

This is an open, prospective, comparative parallel-arm medical device clinical study of Dermalix (Dx) in diabetic foot wounds. Dx is a 3-dimensional collagen-laminin porous-structured dermal matrix prepared and additionally impregnated with resveratrol-loaded hyaluronic acid and dipalmitoylphosphatidylcholine-based microparticles. The aim was to evaluate the efficacy and safety of Dx, an investigational medical device, in Wagner 1 and 2 wounds in comparison to a standard wound care (SWC) that consists of irrigation and cleaning with sterile saline solution. Forty-eight patients were randomized to receive either SWC or SWC + Dx. A 4-week treatment period was followed by a 2-month follow-up without treatment. The wound area measurement, total collagen, vascular epidermal growth factor, tumor necrosis factor, interleukin 1, caspase 3, glutathione, reduced/oxidized glutathione, and lipid peroxidation levels were evaluated. At the end of 4 weeks, the percentage closures of wounds were determined as 57.82% for Dx, and 26.63% for SWC groups. Dx had a significant effect on tumor necrosis factor, caspase 3, and reduced/oxidized glutathione levels. Dx provided 2 times faster wound healing and decreased oxidative stress. Application of Dx in the first phase of wound would help the wound area heal faster with a safe profile.

02
CLINICAL STUDY Die Pharmazie (2024) PMID: 38877681 ↗
Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF₂ /HO-1 signaling.
Clinical Trial Synthesis 2024 Clinical Study published in Die Pharmazie. Key conclusion: Conclusion: The present study introduces clear evidence that the administration of LIX and TIC can improve meta
View Original PubMed Abstract ↓

In this study, we hypothesized that lixisenatide (LIX) and ticagrelor (TIC) could have a protective effect against type 2 diabetes mellitus (T2DM)-induced vascular damage. Furthermore, we explored the possible additional protective effect of co-administering LIX and TIC in the treatment regimen. Methods: 50 male rats were divided into five groups, each comprising 10 rats: C (control), D (T2DM rats), D + LIX (T2DM rats treated with LIX for 4 weeks), D + TIC (T2DM rats treated with TIC for 4 weeks), and D + LIX + TIC (T2DM rats treated with LIX + TIC for 4 weeks). Results: The D group showed an increase in body weight, blood glucose, hemostatic model assessment for insulin resistance (HOMA-IR), aorta reactive oxygen species (ROS), and nuclear factor kappa B (NF-κ B), along with a reduction in serum insulin, aorta superoxide dismutase (SOD), glutathione reduced (GSH), nuclear factor erythroid-2 (NrF₂), hemeoxygenase-1 (HO-1), and endothelial nitric oxide synthase (eNOS). Deterioration in the aorta histopathological condition, coupled with a noticeable impairment in vascular reactivity compared to the C group, was observed. A single administration of LIX showed a reduction in body weight, blood glucose, HOMA-IR, aorta ROS, and NF-κ B, accompanied by an increase in serum insulin, aorta SOD, GSH, NrF₂, HO-1, and eNOS. Amelioration in the aorta histopathological condition and improved vascular reactivity compared to the D group were reported. Similarly, a single administration of TIC showed a reduction in aorta ROS and NF-κ B, along with an increase in aorta SOD, GSH, NrF₂, HO-1, and eNOS. A slight amelioration was detected in the aorta histopathological condition, with improved vascular reactivity compared to the D group. The combined administration of LIX and TIC showed a reduction in aorta ROS and NF-κ B, along with an increase in aorta GSH, SOD, HO-1, and eNOS. This was combined with evident amelioration in the aorta histopathological condition and noticeable improvement in vascular reactivity compared to the single treatment with either LIX or TIC group. Conclusion: The present study introduces clear evidence that the administration of LIX and TIC can improve meta

03
CLINICAL STUDY Archives of pharmacal research (2019) PMID: 31482490 ↗
Synergistic effect of buthionine sulfoximine on the chlorin e6-based photodynamic treatment of cancer cells.
Clinical Trial Synthesis 2019 Clinical Study published in Archives of pharmacal research. Key conclusion: Furthermore, the addition of glutathione reduced ethyl ester (GSH-OEt), recovered intracellular GSH level, and cell viability with reduced the intracellular ROS level.
View Original PubMed Abstract ↓

In this study, we investigated the synergistic effect of L-buthionine sulfoximine (BSO) on the chlorin e6 (Ce6)-based photodynamic therapy (PDT) of cancer cells. Among various cancer cells, HCT116 cells have highest intracellular L-glutathione (GSH) level and SNU478 cells showed the lowest GSH level. BSO alone showed negligible intrinsic cytotoxicity against CCD986sk cells. Since HCT116 and SNU478 cells showed the highest and the lowest intracellular GSH levels, respectively, those were used to test synergistic effect on the Ce6-based PDT. In the absence of light, BSO and Ce6 combination did not practically increase reactive oxygen species (ROS) in either of HCT116 or SNU478 cells, while light irradiation increased ROS level dose-dependently. 10 μM BSO treatment significantly depleted total GSH level in cancer cells, i.e. total GSH level decreased to one-fourth of the control in HCT116 cells while it decreased to two-fifth of the control treatment at SNU478 cell. BSO showed synergistic effect on the ROS production in HCT116 cells while it has practically no benefits in ROS production of SNU478 cells. No synergistic effect was observed in viability of SNU478 cells because BSO itself was cytotoxic to SNU478 cells. However, BSO had negligible cytotoxicity against HCT116 cells and showed synergistic anticancer effect in combination with Ce6-based PDT. Furthermore, the addition of glutathione reduced ethyl ester (GSH-OEt), recovered intracellular GSH level, and cell viability with reduced the intracellular ROS level. We suggest that synergistic effect of BSO in the Ce6-based PDT should be considered with intrinsic intracellular GSH level of cancer cells.

04
CLINICAL STUDY European journal of pharmacology (2017) PMID: 28257823 ↗
Ameliorative effects of sildenafil and/or febuxostat on doxorubicin-induced nephrotoxicity in rats.
Clinical Trial Synthesis 2017 Clinical Study published in European journal of pharmacology. Key conclusion: sildenafil and febuxostat are promising protective agents against doxorubicin-nephrotoxicity through improving biochemical, inflammatory, histopathological and immunohistochemical alterations induced by doxorubicin.
View Original PubMed Abstract ↓

Sildenafil and febuxostat protect against doxorubicin-induced nephrotoxicity; however the exact mechanism remains to be elucidated. The effect of sildenafil and febuxostat on doxorubicin-induced nephrotoxicity in rats was studied. Male rats were subdivided into nine groups. The 1st group served as normal control, the 2nd group received dimethylsulfoxide 50% (DMSO), the 3rd group received doxorubicin (3.5mg/kg, i.p.), twice weekly for 3 weeks. The next 3 groups received sildenafil (5mg/kg; p.o.), febuxostat (10mg/kg; p.o.) and their combination, respectively daily for 21 days. The last 3 groups received doxorubicin in combination with sildenafil, febuxostat or their combination. Nephrotoxicity was evaluated histopathologically by light microscopy and biochemically through measuring the following parameters, Kidney function biomarkers [serum levels of urea, creatinine and uric acid], oxidative stress biomarkers [kidney contents of glutathione reduced (GSH) and malondialdehyde (MDA)], The apoptotic marker namely; caspase-3 in kidney tissue and the inflammatory mediator tumor necrosis factor alpha (TNF-α). doxorubicin-induced a significant elevation in nephrotoxicity markers, expression of caspase-3 and caused induction of inflammation and oxidative stress. Histological changes in the kidney was tubular necrosis. Sildenafil and/or febuxostat administration with doxorubicin caused a significant decrease in nephrotoxicity markers and inflammatory mediators, restoration of normal values of oxidative stress biomarkers and hampering the expression of renal caspase-3. They also ameliorate histological changes induced by doxorubicin. sildenafil and febuxostat are promising protective agents against doxorubicin-nephrotoxicity through improving biochemical, inflammatory, histopathological and immunohistochemical alterations induced by doxorubicin.

05
CLINICAL STUDY Environmental toxicology and pharmacology (2016) PMID: 27513569 ↗
Combination of chlorogenic acid and salvianolic acid B protects against polychlorinated biphenyls-induced oxidative stress through Nrf2.
Clinical Trial Synthesis 2016 Clinical Study published in Environmental toxicology and pharmacology. Key conclusion: We found that pretreatment with CGA, Sal B, and CGA plus Sal B effectively attenuated liver injury and cytotoxicity caused by PCB126, but improved the expressions of superoxide dismutase (SOD), glutathione reduced (GSH), heme oxygenase-1 (HO-1) and nuclear factor E2-related facto
View Original PubMed Abstract ↓

Caffeic acid derivatives (CADs) are well-known phytochemicals with multiple physiological and pharmacological activities. This study aimed to investigate the combined protective effects of CADs on PCB126-induced liver damages and oxidative stress in mice. Here, we used chemiluminescence and chose chlorogenic acid (CGA), salvianolic acid B (Sal B) as the best antioxidants. Then, mice were intragastrically administered with 60mg/kg/d CGA, Sal B, and CGA plus Sal B (1:1) for 3 weeks before exposing to 0.05mg/kg/d PCB126 for 2 weeks. We found that pretreatment with CGA, Sal B, and CGA plus Sal B effectively attenuated liver injury and cytotoxicity caused by PCB126, but improved the expressions of superoxide dismutase (SOD), glutathione reduced (GSH), heme oxygenase-1 (HO-1) and nuclear factor E2-related factor 2 (Nrf2), CGA plus Sal B especially, was found to have the best effects that indicated a synergetic protective effect. Taken together, as the Nrf2 regulates the cyto-protective response by up-regulating the expression of antioxidant genes, we suggested that CGA plus Sal B had a combined protection on PCB126-induced tissue damages and that the Nrf2 signaling might be involved.

06
CLINICAL STUDY Toxicology in vitro (2013) PMID: 23850985 ↗
Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system.
Clinical Trial Synthesis 2013 Clinical Study published in Toxicology in vitro. Key conclusion: These findings provide insight on the safety and drug-herb interactions of the Curcuma species.
View Original PubMed Abstract ↓

Misclassification of Curcuma species (family Zingiberaceae) may lead to unwanted human exposure to Curcuma elata sesquiterpenes zederone and germacrone which have caused hepatotoxicity and changes in CYP expression in laboratory animals. We investigated how these compounds interact with the human cytochrome P450 (CYP) system, in order to evaluate their potential for human liver toxicity and herb-drug interactions. We found that both sesquiterpenes (1-30 μM) greatly induced expression of CYP2B6 and CYP3A4 but not CYP1A2 mRNAs in human primary hepatocytes (HPHs). This induction profile correlated with activation of constitutive androstane and pregnane X receptors. Cytotoxicity was also observed in exposed HPHs. CYP inhibition studies with pooled human liver microsomes (HLMs) indicated that zederone and germacrone moderately inhibited CYP2B6 and CYP3A4 activities in vitro, with IC50 values below 10 μM. When zederone was incubated with HLMs and NADPH, one di-epoxide metabolite was formed and by using glutathione trapping, five epoxide-derived conjugates were detected. Germacrone produced two oxidized metabolites and four glutathione conjugates. The results suggest that enzymes in HLMs convert sesquiterpenes into reactive, electrophilic compounds which may be causative for the reported liver injuries. These findings provide insight on the safety and drug-herb interactions of the Curcuma species.

07
CLINICAL STUDY Journal of proteome research (2009) PMID: 19754040 ↗
Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: endogenous ROS augmentation.
Clinical Trial Synthesis 2009 Clinical Study published in Journal of proteome research. Key conclusion: In addition, checkerboard microdilution assay showed that addition of antioxidant ascorbic acid or reduced glutathione reduced the synergistic antifungal activity of FLC + BBR significantly.
View Original PubMed Abstract ↓

Our previous study showed that concomitant use of berberine (BBR) and fluconazole (FLC) provided a synergistic action against FLC-resistant Candida albicans (C. albicans) clinical strains in vitro. To clarify the mechanism underlying this action, we performed a comparative proteomic study in untreated control cells and cells treated with FLC and/or BBR in 2 clinical strains of C. albicans resistant to FLC. Our analyses identified 16 differentially expressed proteins, most of which were related to energy metabolisms (e.g., Gap1, Adh1, and Aco1). Functional analyses revealed that FLC + BBR treatment increased mitochondrial membrane potential, decreased intracellular ATP level, inhibited ATP-synthase activity, and increased generation of endogenous reactive oxygen species (ROS) in FLC-resistant strains. In addition, checkerboard microdilution assay showed that addition of antioxidant ascorbic acid or reduced glutathione reduced the synergistic antifungal activity of FLC + BBR significantly. These results suggest that mitochondrial aerobic respiration shift and endogenous ROS augmentation contribute to the synergistic action of FLC + BBR against FLC-resistant C. albicans.

08
CLINICAL STUDY Neuroscience research (2009) PMID: 19367792 ↗
Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide.
Clinical Trial Synthesis 2009 Clinical Study published in Neuroscience research. Key conclusion: The effects were significant as compared to their effect per se.Study highlights the therapeutic potential of these drugs in the treatment of Huntington's disease.
View Original PubMed Abstract ↓

Cyclosporine and FK506, a well-known immunosuppressant drugs that are presently being used for prevention of allograft rejection. Recently, several studies suggest their therapeutic potential in the treatment of neurodegenerative diseases. Therefore, present study was conducted to explore their therapeutic potential against 3-nitropropionic acid induced cognitive dysfunctions and biochemical alterations in striatum, cortex and hippocampal regions of brain. Further, attempt has also been made to investigate their possible interaction with nitric oxide modulators.3-Nitropropionic acid (10 mg/kg) for 14 days treatment significantly impaired cognitive task as evidenced by Morris water as well as plus maze performance tasks. 3-Nitropropionic acid treatment significantly disturbed glutathione redox ratio and different levels of glutathione (as indicated by alterations in total glutathione, reduced glutathione, oxidized glutathione, glutathione-S-transferase levels). Acetylcholinesterase enzyme activity was also significantly disturbed by 3-NP treatment. Further, FK-506 (0.5, 1 and 2 mg/kg, p.o.) and cyclosporine (2.5, 5 and 10 mg/kg, p.o.) treatment significantly improved cognitive functions both in Morris water maze and plus maze tasks. Beside these drug treatment significantly attenuated oxidative stress as evidenced by restoring different glutathione levels and acetylcholinesterase activity as compared to control (3-NP treated) animals. Further sub effective doses of cyclosporine (5 mg/kg) and FK-506 (1 mg/kg) effect was potentated by l-NAME and reversed by l-arginine pretreatment. The effects were significant as compared to their effect per se.Study highlights the therapeutic potential of these drugs in the treatment of Huntington's disease. Study further suggest that nitric oxide modulation in involved in the neuroprotective effect of these drugs against 3-NP neurotoxicity.

09
CLINICAL STUDY Chemosphere (2002) PMID: 11827286 ↗
Oxidative stress induced by HCH in Hydrilla verticillata (l.f.) Royle: modulation in uptake and toxicity due to Fe.
Clinical Trial Synthesis 2002 Clinical Study published in Chemosphere. Key conclusion: In contrast, the accumulation of Fe was increased in presence of HCH at higher concentrations.
View Original PubMed Abstract ↓

The effect of hexachlorocyclohexane (HCH) singly and in combination with iron was studied on chlorophyll, malondialdehyde, cysteine, total -SH contents and potassium ion leakage in the plants of Hydrilla verticillata. The effect of HCH was also studied on glutathione (reduced and oxidised) content and superoxide dismutase activity. The results showed an increase in malondialdehyde content and potassium ion leakage with increase in HCH concentrations, however, the presence of Fe played a protective role. The chlorophyll content was decreased with increase in HCH concentrations and exposure period. However, the chlorophyll content at 2 and 5 microg ml(-1) was significantly higher in HCH-treated plants as compared to HCH + Fe after 168 h, showing protective role of Fe. The results showed significant increase up to 1 microg ml(-1) in cysteine content with increase in concentrations in both the treatments. The total -SH content was increased with increase in concentrations in both the treatments. In HCH-treated plants, non-significant change was noticed in reduced glutathione (GSH) content however, oxidised glutathione (GSSG) content was increased significantly after 168 h, indicative of oxidative stress. In addition, superoxide dismutase activity was increased non-significantly with increase in HCH concentrations. The accumulation of HCH singly and in presence of Fe was concentration- and duration-dependent. The accumulation of HCH was decreased in presence of Fe at higher concentrations. In contrast, the accumulation of Fe was increased in presence of HCH at higher concentrations. The results showed that malondialdehyde content and potassium ions leakage are the primary responses of toxicity.

10
CLINICAL STUDY Yakugaku zasshi (1999) PMID: 10630099 ↗
[Effects of allopurinol for oxidative injury of cisplatin-induced nephrotoxicity in mice].
Clinical Trial Synthesis 1999 Clinical Study published in Yakugaku zasshi. Key conclusion: Especially in the CDDP + Allop group, the increase of mesangium cells in the glomeruli was observed.
View Original PubMed Abstract ↓

The effects of allopurinol (Allop) on the lipid peroxidation in the nephrotoxicity of an antitumor drug, cisplatin (CDDP) were studied in mice. CDDP was administered intraperitoneally to two groups (CDDP + Allop group and CDDP + CMC-Na group) at single doses of 10 mg/kg, and mice were sacrificed 3 days after CDDP administration. The body weights of the CDDP-administered group gradually decreased to approximately 78% of the values of the control group (saline + Allop group and saline + CMC-Na group) within 3 days. Plasma urea nitrogen and creatinine, especially in the CDDP + Allop group, increased after 3 days. Lipid peroxides in the blood and kidney were monitored by measuring the production of malondialdehyde (MDA), which increased in the CDDP + CMC-Na group. On the other hand, MDA levels in the CDDP + Allop group increased in the kidney but remained unchanged in the blood. Changes were observed in tissue glutathione (reduced form, GSH; oxidized form, GSSG) levels in the CDDP + Allop group but not in the CDDP + CMC-Na group. Histomorphological examination demonstrated the degeneration of the proximal tubuli in the CDDP-administered groups. Especially in the CDDP + Allop group, the increase of mesangium cells in the glomeruli was observed. From these results, it was suggested that Allop was not able to inhibit CDDP-induced lipid peroxidation in the kidney, and the kidney function became more severely impaired by the administration of Allop.

RELATED MONOGRAPHS

Related Monographs in This Category